Alnylam Pharmaceuticals (ALNY) Cash from Operations (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cash from Operations for 18 consecutive years, with $326.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 151.7% year-over-year to $326.7 million; the trailing twelve-month figure through Jun 2026 stood at $911.8 million (up 2299.26% YoY), and the FY2025 full-year result was $524.1 million, up 6405.1% from the prior year.
• Cash from Operations grew to $326.7 million in Q2 2026 per ALNY's latest filing, from $70.5 million in the prior quarter.
• Across five years, Cash from Operations topped out at $359.4 million in Q3 2023 and bottomed at -$171.2 million in Q1 2022.
• Historically, Cash from Operations has averaged $26.4 million across 5 years, with a median of -$44.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 217.71% in 2024, then surged 703.14% in 2025.
• Over 5 years, Cash from Operations stood at -$132.0 million in 2022, then surged by 77.42% to -$29.8 million in 2023, then sank by 217.71% to -$94.7 million in 2024, then soared by 272.78% to $163.6 million in 2025, then jumped by 99.76% to $326.7 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $326.7 million, $70.5 million, and $163.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.